Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients

• Status: Unknown status
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether aliskiren, a direct renin inhibitor, compared with amlodipine, a calcium channel blocker, reduces mortality and cardiovascular events in these high-risk patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second University of Naples; University of Campania "Luigi Vanvitelli"
• Collaborator: IRCCS San Raffaele
• Treatments: Amlodipine

Criteria

Inclusion Criteria:

• hemodialysed patients

• predialytic blood pressure greater or equal to 140/90 mmHg

Exclusion Criteria:

• history of heart failure

• history of ischemic heart disease

• severe aortic stenosis

• known allergy to aliskiren or amlodipine

• severe disorders of liver function